7BEB8582A6D4589A8725881B0077CA4F Hearing Summary

The committee recessed.

The committee came back to order.

Representative Neville and Representative Ortiz, co-prime bill sponsors, presented House Bill 22-1344, concerning the lawful use of a prescription drug that contains 3,4-methylenedioxymethamphetamine (MDMA) that is approved by the United States food and drug administration.  Under current law, MDMA is a schedule I controlled substance.  The bill specifies that prescription drugs containing MDMA, approved by the federal Food and Drug Administration, and placed on a schedule other than schedule I are legal to prescribe, dispense, transport, possess, and use in Colorado.

The bill sponsors responded to questions from the committee.

Jonathan Lubecky, representing the Multidisciplinary Association for Psychedelic Studies (MAPS) Public Benefit Corporation, testified in support of the bill.

Dr. Will Van Derveer, representing self, testified in support of the bill.

Marcela Ot'alora G, representing MAPS, testified in support of the bill.

The panelists responded to questions from the committee.

Representative Ortiz explained amendments L.001 and L.002 (Attachments L and M).

Representative Ortiz and Representative Neville provided concluding remarks about the bill. Committee members commented on the bill.